Cargando…

Image analysis-based tumor infiltrating lymphocytes measurement predicts breast cancer pathologic complete response in SWOG S0800 neoadjuvant chemotherapy trial

We assessed the predictive value of an image analysis-based tumor-infiltrating lymphocytes (TILs) score for pathologic complete response (pCR) and event-free survival in breast cancer (BC). About 113 pretreatment samples were analyzed from patients with stage IIB-IIIC HER-2-negative BC randomized to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fanucci, Kristina A., Bai, Yalai, Pelekanou, Vasiliki, Nahleh, Zeina A., Shafi, Saba, Burela, Sneha, Barlow, William E., Sharma, Priyanka, Thompson, Alastair M., Godwin, Andrew K., Rimm, David L., Hortobagyi, Gabriel N., Liu, Yihan, Wang, Leona, Wei, Wei, Pusztai, Lajos, Blenman, Kim R. M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10182981/ https://www.ncbi.nlm.nih.gov/pubmed/37179362 http://dx.doi.org/10.1038/s41523-023-00535-0

Ejemplares similares

Immune profiling of pre- and post-treatment breast cancer tissues from the SWOG S0800 neoadjuvant trial
por: Li, Xiaotong, et al.
Publicado: (2019)

SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer
por: Nahleh, Z. A., et al.
Publicado: (2016)

Tumor immune microenvironment of self-identified African American and non-African American triple negative breast cancer
por: Marczyk, Michal, et al.
Publicado: (2022)

Pre-treatment Amino Acids and Risk of Paclitaxel-induced Peripheral Neuropathy in SWOG S0221
por: Chen, Ciao-Sin, et al.
Publicado: (2023)

Evaluation of the Sensitivity to Endocrine Therapy Index and 21-Gene Breast Recurrence Score in the SWOG S8814 Trial
por: Speers, Corey W., et al.
Publicado: (2023)

Immunological Differences Between Immune-Rich Estrogen Receptor–Positive and Immune-Rich Triple-Negative Breast Cancers
por: O’Meara, Tess, et al.
Publicado: (2020)

Quantitative assessment of the immune microenvironment in African American Triple Negative Breast Cancer: a case–control study
por: Yaghoobi, Vesal, et al.
Publicado: (2021)

Thymidine kinase activity levels in serum can identify HR+ metastatic breast cancer patients with a low risk of early progression (SWOG S0226)
por: Bergqvist, Mattias, et al.
Publicado: (2023)

CD68, CD163, and matrix metalloproteinase 9 (MMP-9) co-localization in breast tumor microenvironment predicts survival differently in ER-positive and -negative cancers
por: Pelekanou, Vasiliki, et al.
Publicado: (2018)

Effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes and PD-L1 expression in breast cancer and its clinical significance
por: Pelekanou, Vasiliki, et al.
Publicado: (2017)

Erratum to: Effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes and PD-L1 expression in breast cancer and its clinical significance
por: Pelekanou, Vasiliki, et al.
Publicado: (2017)

Friday 5 September, 0800–1000 Concurrent Session: Radiation Oncology Varian Prize
Publicado: (2014)

Comparison of PD-L1 protein expression between primary tumors and metastatic lesions in triple negative breast cancers
por: Rozenblit, Mariya, et al.
Publicado: (2020)

A phase II study of docetaxel and vinorelbine plus filgrastim for HER-2 negative, stage IV breast cancer: SWOG S0102
por: Gralow, Julie R., et al.
Publicado: (2013)

Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer
por: Foldi, Julia, et al.
Publicado: (2021)

Author Correction: Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer
por: Foldi, Julia, et al.
Publicado: (2022)

Digital Spatial Profiling Links Beta-2-microglobulin Expression with Immune Checkpoint Blockade Outcomes in Head and Neck Squamous Cell Carcinoma
por: Gavrielatou, Niki, et al.
Publicado: (2023)

Compte rendu de machine development 19.2.197o 0600 - 0800 high energy "q" measurements
por: Azzoni, G
Publicado: (1970)

Impact of a randomized weight loss trial on breast tissue markers in breast cancer survivors
por: Dieli-Conwright, Christina M., et al.
Publicado: (2022)

Stochastic extraction at 10 GeV/c: Machine development report (31 May 1979, 00.00-08.00)
por: Cappi, R, et al.
Publicado: (1979)

Identification and Validation of a Novel Biologics Target in Triple Negative Breast Cancer
por: Wali, Vikram B., et al.
Publicado: (2019)

Drug-drug interactions in subjects enrolled in SWOG trials of oral chemotherapy
por: Marcath, Lauren A., et al.
Publicado: (2021)

An evaluation of stakeholder engagement in comparative effectiveness research: lessons learned from SWOG S1415CD
por: Bell-Brown, Ari, et al.
Publicado: (2022)

Quantitative, Spatially Defined Expression of Leukocyte-associated Immunoglobulin-like Receptor in Non–small Cell Lung Cancer
por: Aung, Thazin N., et al.
Publicado: (2023)

Higher capecitabine AUC in elderly patients with advanced colorectal cancer (SWOGS0030)
por: Louie, S G, et al.
Publicado: (2013)

Improved outcomes with “7+3” induction chemotherapy for acute myeloid leukemia over the past four decades: analysis of SWOG trial data
por: Othus, Megan, et al.
Publicado: (2022)

AML risk stratification models utilizing ELN-2017 guidelines and additional prognostic factors: a SWOG report
por: Pogosova-Agadjanyan, Era L., et al.
Publicado: (2020)

Characteristics and prognostic impact of IDH mutations in AML: a COG, SWOG, and ECOG analysis
por: Zarnegar-Lumley, Sara, et al.
Publicado: (2023)

Genomic and Immune Profiling of a Patient With Triple-Negative Breast Cancer That Progressed During Neoadjuvant Chemotherapy Plus PD-L1 Blockade
por: Casadevall, David, et al.
Publicado: (2019)

Run 115 - 21st October 1971 - 07.00 to 08.00h, Rings 1 and 2 - 26 GeV/c: Physics beams
por: Bryant, P J
Publicado: (1971)

Body Mass Index and Weight Loss in Metastatic Colorectal Cancer in CALGB (Alliance)/SWOG 80405
por: Guercio, Brendan J, et al.
Publicado: (2020)

Tumor-Derived Extracellular Vesicles as Complementary Prognostic Factors to Circulating Tumor Cells in Metastatic Breast Cancer
por: Nanou, Afroditi, et al.
Publicado: (2023)

Successes and challenges of implementing a cancer care delivery intervention in community oncology practices: lessons learned from SWOG S1415CD
por: Watabayashi, Kate K., et al.
Publicado: (2022)

Germline genetic variants in ABCB1, ABCC1, and ALDH1A1 and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer
por: Yao, Song, et al.
Publicado: (2013)

Rhodococcus equi venous catheter infection: a case report and review of the literature
por: Guerrero, Rosalinda, et al.
Publicado: (2011)

S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma
por: El-Khoueiry, A B, et al.
Publicado: (2014)

Phase II Trial of Sorafenib in Combination with Carboplatin and Paclitaxel in Patients with Metastatic Uveal Melanoma: SWOG S0512
por: Bhatia, Shailender, et al.
Publicado: (2012)

Antiviral therapy use and related outcomes in patients with cancer and viral infections: results from SWOG S1204
por: Hwang, Jessica P., et al.
Publicado: (2022)

Molecular differences between younger versus older ER-positive and HER2-negative breast cancers
por: Qing, Tao, et al.
Publicado: (2022)

Gene expression profiling of breast cancer
por: Pusztai, Lajos
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_ouja70vvb1gsgd0bnogbveo70h